Search Results - "Barbara Adamo"

Clinical implications of the intrinsic molecular subtypes of breast cancer by Prat, Aleix, Pineda, Estela, Adamo, Barbara, Galván, Patricia, Fernández, Aranzazu, Gaba, Lydia, Díez, Marc, Viladot, Margarita, Arance, Ana, Muñoz, Montserrat

“…Abstract Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular…”
Get full text

Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

“…The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced…”
Get full text

Molecular Characterization of Basal‐Like and Non‐Basal‐Like Triple‐Negative Breast Cancer by Prat, Aleix, Adamo, Barbara, Cheang, Maggie C.U., Anders, Carey K., Carey, Lisa A., Perou, Charles M.

“…Learning Objectives Contrast the definitions of TN and basal‐like. Describe the undistinguishable global gene expression patterns of non‐basal‐like TN tumors…”
Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix

“…Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of…”
Get full text

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis by Schettini, Francesco, Pascual, Tomás, Conte, Benedetta, Chic, Nuria, Brasó-Maristany, Fara, Galván, Patricia, Martínez, Olga, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Fernández-Martinez, Aranzazu, Rognoni, Carla, Griguolo, Gaia, Guarneri, Valentina, Conte, Pier Franco, Locci, Mariavittoria, Brase, Jan C., Gonzalez-Farre, Blanca, Villagrasa, Patricia, De Placido, Sabino, Schiff, Rachel, Veeraraghavan, Jamunarani, Rimawi, Mothaffar F., Osborne, C. Kent, Pernas, Sonia, Perou, Charles M., Carey, Lisa A., Prat, Aleix

“…•We correlated the breast cancer intrinsic subtypes with pCR in HER2+ disease.•The HER2-E subtype was significantly and consistently associated with pCR after…”
Get full text

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes by Prat, Aleix, Karginova, Olga, Parker, Joel S., Fan, Cheng, He, Xiaping, Bixby, Lisa, Harrell, J. Chuck, Roman, Erick, Adamo, Barbara, Troester, Melissa, Perou, Charles M.

“…Five molecular subtypes (luminal A, luminal B, HER2-enriched, basal-like, and claudin-low) with clinical implications exist in breast cancer. Here, we…”
Get full text

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade by Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

“…The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors…”
Get full text

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer by Prat, Aleix, Brasó-Maristany, Fara, Martínez-Sáez, Olga, Sanfeliu, Esther, Xia, Youli, Bellet, Meritxell, Galván, Patricia, Martínez, Débora, Pascual, Tomás, Marín-Aguilera, Mercedes, Rodríguez, Anna, Chic, Nuria, Adamo, Barbara, Paré, Laia, Vidal, Maria, Margelí, Mireia, Ballana, Ester, Gómez-Rey, Marina, Oliveira, Mafalda, Felip, Eudald, Matito, Judit, Sánchez-Bayona, Rodrigo, Suñol, Anna, Saura, Cristina, Ciruelos, Eva, Tolosa, Pablo, Muñoz, Montserrat, González-Farré, Blanca, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Vivancos, Ana

“…Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with…”
Get full text

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study by García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, Schettini, Francesco

“…Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need…”
Get full text

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients by Ricciardi, Giuseppina Rosaria Rita, Adamo, Barbara, Ieni, Antonio, Licata, Luana, Cardia, Roberta, Ferraro, Giuseppa, Franchina, Tindara, Tuccari, Giovanni, Adamo, Vincenzo

“…TNBC is an aggressive subset of breast cancer (BC) without specific target therapy. This observational, retrospective study included 45 cases of TNBC. The aim…”
Get full text

Gene expression profiles of breast cancer metastasis according to organ site by Brasó‐Maristany, Fara, Paré, Laia, Chic, Nuria, Martínez‐Sáez, Olga, Pascual, Tomás, Mallafré‐Larrosa, Meritxell, Schettini, Francesco, González‐Farré, Blanca, Sanfeliu, Esther, Martínez, Débora, Galván, Patricia, Barnadas, Esther, Salinas, Belinda, Tolosa, Pablo, Ciruelos, Eva, Carcelero, Esther, Guillén, Cecilia, Adamo, Barbara, Moreno, Reinaldo, Vidal, Maria, Muñoz, Montserrat, Prat, Aleix

“…In advanced breast cancer, biomarker identification and patient selection using a metastatic tumor biopsy is becoming more necessary. However, the biology of…”
Get full text

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial by Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A, Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

“…The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive…”
Get full text

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer by Lorman-Carbó, Natàlia, Martínez-Sáez, Olga, Fernandez-Martinez, Aranzazu, Galván, Patricia, Chic, Nuria, Garcia-Fructuoso, Isabel, Rodríguez, Adela, Gómez-Bravo, Raquel, Schettini, Francesco, Blasco, Paula, Castillo, Oleguer, González-Farré, Blanca, Adamo, Barbara, Vidal, Maria, Muñoz, Montserrat, Perou, Charles M., Malumbres, Marcos, Gavilá, Joaquín, Pascual, Tomás, Prat, Aleix, Brasó-Maristany, Fara

“…This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase…”
Get full text

Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer by Anders, Carey K, Adamo, Barbara, Karginova, Olga, Deal, Allison M, Rawal, Sumit, Darr, David, Schorzman, Allison, Santos, Charlene, Bash, Ryan, Kafri, Tal, Carey, Lisa, Miller, C Ryan, Perou, Charles M, Sharpless, Norman, Zamboni, William C

“…Breast cancer brain metastases (BCBM) are a challenging consequence of advanced BC. Nanoparticle agents, including liposomes, have shown enhanced delivery to…”
Get full text

Current status of fertility preservation in a Spanish tertiary public hospital: multidisciplinary approach and experience in over 1500 patients by Barral, Yasmina, Borrás, Aina, Carrillo, Pilar, Agustí, Inés, Peralta, Sara, Casals, Gemma, Fàbregues, Francesc, Guimerà, Marta, Corral, Juan Manuel, Calafell, Josep Maria, Redondo, Miriam, Glickman, Ariel, Rovira, Montserrat, Adamo, Bárbara, Ricart, Elena, Trullàs, Dolors Manau

“…Purpose Currently, 15% of gynaecological and 9% of haematological malignancies are diagnosed before the age of 40. The increased survival rates of cancer…”
Get full text

Stratifying triple-negative breast cancer: which definition(s) to use? by Adamo, Barbara, Anders, Carey K

“…Triple-negative breast cancers (TNBC) have increased rates of pathologic complete response following neoadjuvant chemotherapy, yet have poorer prognosis…”
Get full text

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients by Ricciardi, Giuseppina Rosaria Rita, Adamo, Barbara, Ieni, Antonio, Licata, Luana, Cardia, Roberta, Ferraro, Giuseppa, Franchina, Tindara, Tuccari, Giovanni, Adamo, Vincenzo

“…Legend: [A, B] E-cadherin negative/positive staining; [C,D] Ki-67 level < or ≥ 20%; [E,F] negative/positive AR staining…”
Get full text

The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population by Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Adamo, Barbara, Ferraro, Giuseppa, Franchina, Tindara, Rossello, Rosalba, Zanghì, Mariangela, Cicero, Giuseppe, Rizzo, Sergio, Caristi, Nicola, Russo, Antonio

“…Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2…”
Get more information

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy by Chic, Nuria, Schettini, Francesco, Brasó-Maristany, Fara, Sanfeliu, Esther, Adamo, Barbara, Vidal, Maria, Martínez, Débora, Galván, Patricia, González-Farré, Blanca, Cortés, Javier, Gavilá, Joaquín, Saura, Cristina, Oliveira, Mafalda, Pernas, Sònia, Martínez-Sáez, Olga, Soberino, Jesús, Ciruelos, Eva, Carey, Lisa A., Muñoz, Montserrat, Perou, Charles M., Pascual, Tomás, Bellet, Meritxell, Prat, Aleix

“…Chemotherapy efficacy in early-stage hormone receptor-positive (HR+) breast cancer (BC) according to menopausal status needs a biological explanation. We…”
Get full text

A rare case of malignant solitary fibrous tumor of the spinal cord by Muñoz, Eva, Prat, Aleix, Adamo, Barbara, Peralta, Sergio, Ramón y Cajal, Santiago, Valverde, Claudia

“…Case report. We present a case of an ambulatory patient with a solitary fibrous tumor of the spinal cord. Solitary fibrous tumor (SFT) is an uncommon…”
Get full text